Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials

Back

ESC Professional Premium Access

Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials

Session: Antidiabetic medications and cardiovascular disease

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor R. Kani (Kamogawa, JP)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Ryoma Kani

Kameda Medical Center, Kamogawa (Japan)

0 follower

6 more presentations in this session

Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study

Speaker: Assistant Professor Y. Chen (Taichung, TW)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus

Speaker: Professor Y. Oh (Seoul, KR)

Access

Abstract

Slides

GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study

Speaker: Ms K. Soerensen (Copenhagen, DK)

The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor

Speaker: Doctor C. Chen (Taipei, TW)

Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity sc

Speaker: Professor G. Tse (Hong Kong, CN)

Access the full session

Antidiabetic medications and cardiovascular disease

Speakers: Doctor R. Kani, Assistant Professor Y. Chen, Professor Y. Oh, Ms K. Soerensen, Doctor C. Chen...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources